acm-001
VaccineexperimentalCOVID-19
Clinical trial activity
2 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Nov 26, 2021 (NCT06028321)
Timeline
2020s
- Jan 1, 2021
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
Mechanism of action
- SARS-CoV-2Immunity, active
SARS-CoV-2 immunity, active
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05385991 | Phase 1 | Jul 1, 2022 | ACM Global Laboratories |
| NCT06028321 | Phase 1 | Nov 26, 2021 | Actimed Therapeutics Ltd, Quotient |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| ACM Global Laboratories | For profit | 1 | 1 | 1 | 2022 |
| Actimed Therapeutics Ltd | For profit | 1 | 1 | 1 | 2021 |
| Quotient | For profit | 1 | 0 | 1 | 2021 |
3 organizations
Page 1 / 1